Latest Asia Pacific Expansion News

Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.

ReNerve Limited has secured market approval for its NervAlign® Nerve Cuff in Malaysia, marking a key milestone in its Asia-Pacific expansion strategy. This approval follows earlier clearances in Hong Kong and Thailand, positioning the company to tap into a growing regional nerve repair market.

Vection Technologies has announced the acquisition of Monogic Limited, a digital marketing agency based in Hong Kong and Singapore, marking a significant step in its Asia Pacific expansion strategy. The deal enhances Vection’s AI and XR capabilities while adding immediate revenue and earnings contributions.

DXN Limited reports a sharp revenue decline in Q1 FY26 due to client-driven project deferrals but highlights a robust $11.9 million backlog and the imminent launch of its first Data Centre as a Service site.

Cogstate Limited reports a record-breaking quarter with sales contracts soaring 88% year-on-year, driven by expanding markets and new therapeutic areas. The company signals continued investment in growth initiatives, including AI and Asia-Pacific expansion, while projecting a strong first half of FY26.

Halo Technologies has appointed Peter Oxlade as CEO and George Paxton as COO, aligning leadership with its recent $3.9 million capital raise to fuel expansion across the Asia-Pacific region.

Osteopore Limited has won tender bids to supply its innovative orthopaedic implants to two major public hospitals in Vietnam, marking a significant step in its Asia Pacific expansion.

Yojee Limited has introduced its next-generation freight forwarding platform, MOSAIC, at the IFCBAA National Conference, aiming to disrupt traditional logistics software with AI-driven, community-focused technology.

ClearVue Technologies has inked a five-year exclusive manufacturing and distribution agreement with New Zealand’s Viridian Glass, marking its strategic entry into the New Zealand market with solar-integrated glazing solutions.

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.